On April 4, 2022 RS Oncology, LLC, (RSO) a biotechnical company focused on the treatment of patients with malignant pleural effusion and mesothelioma, reported the dosing of the first patient with RSO-021 as part of its first-in-human Phase 1/2 clinical trial (MITOPE) at the University Hospitals of Leicester in the U.K (Press release, RS Oncology, APR 4, 2022, View Source [SID1234611390]). RSO will be evaluating its novel treatment, RSO-021, against a specific mitochondrial enzyme regulating oxidative stress pathways in cancer cells.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This novel therapeutic approach has proven in pre-clinical studies to significantly reduce tumor burden in malignant mesothelioma and other cancer types by irreversibly binding and inhibiting a key enzyme in the antioxidant signaling network within the mitochondria of malignant cells.
"Our team is excited to begin patient dosing with our novel metabolic therapy. This is a significant milestone in developing a treatment for people suffering from this horrible disease," stated CEO Jarrett Duncan. "We are eager to see activity of our drug in humans following our successful pre-clinical studies in multiple indications," added COO and Head of Business Development, George Naumov, Ph.D.
"Mesothelioma remains a lethal cancer lacking effective treatments, particularly in patients with relapsed disease. This exciting study of a first in class PRX3 inhibitor is hoped to show promising signals that could lead to development of a new approach to tackle this cancer." said the clinical investigator from Leicester Hospital, Professor Dean Fennell, FRCP FRSB.
About MITOPE clinical trial
The MITOPE Phase 1/2 clinical trial is a first-in-human study that will evaluate RSO-021 as a treatment for patients suffering from MPE and mesothelioma. RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage. The MITOPE trial is planned to open in six UK-based clinical institutions and will be recruiting patients in collaboration with Mesothelioma UK. For more MITOPE information review View Source or contact [email protected]. The study is supported by NIHR.